![]() ![]() Bursts - or packets of electricity, tailored to your needs, if you will again - are coordinated and correlated rhythms of pain relief to multiple sites in the body that can stir hardened feelings from years of living with pain with the sensation of a new possibility: The potential for living without severe pain. Rather than tonic treatment - in SCS, simply speaking it's the idea of a consistent and constant pounding of electrical impulses that can leave a person with an unpleasant tingling - the key and the clue to the BurstDR invention is in its name. Like "Blue," Proclaim Plus spinal cord stimulation (SCS) with FlexBurst360 builds on the revolutionary advancements offered by BurstDR. Retrospective reviews decades on, including by Leonard Bernstein, hailed a composition that you can cut parts, interchange sections, add new cadenzas - packets of music, tailored to your tastes, if you will - and it’s still "Rhapsody in Blue."īurton, medical director of Abbott’s neuromodulation business, and his team have orchestrated their own sit-up-and-take-notice piece. Contemporary reviews hailed it not as one idea, but rather several correlated, combined and contrasting rhythms stirring hardened concertgoers with the sensation of a new voice. ![]() ![]() The infinite loop of Gershwin’s "Rhapsody in Blue" that aurally connects Concourses B and C is perhaps the perfect musical accompaniment for this conversation.Īfter all, when "Blue" debuted to the world in 1924, it was revolutionary for an age defined by invention: Jazz. All rights reserved.Allen Burton is changing planes at O'Hare Airport and, as anyone who's made the ride along the moving walkway in Terminal 1 knows, George Gershwin is his traveling companion for at least this part of his journey. Benzinga does not provide investment advice. This article Back Off, Chronic Pain! FDA Nods for Abbott's Spinal Cord Stimulation Devices originally appeared on Price Action: ABT shares are down 0.12% at $109.71 on the last check Tuesday.ĭon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better. On average, people who received SCS therapy experienced a 69.7% reduction in pain.īurstDR is a form of stimulation therapy that uses pulses-or bursts-of mild electrical energy without an abnormal sensation of "tingling" (known as paresthesia) to change pain signals as they travel from the spinal cord to the brain. ħ2.6% of people in the SCS study arm and 85.2% of those implanted achieved significant back pain reduction compared to only 7.1% in the conservative medical management arm.ĩ1.4% of people who received SCS therapy obtained significant pain relief or significantly improved function. Results at six months for the first 200 patients demonstrated clear clinical evidence supporting BurstDR stimulation therapy as an effective treatment for chronic back pain and were sustained at the 12-month follow-up.Īlso Read: Claims of PediaSure Boosting Children's Height Challenged in Lawsuit Against Abbott Laboratories. The FDA approved Abbott Laboratories (NYSE: ABT) spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.Ībbott's DISTINCT study enrolled 270 participants who suffered pain for an average of 12.8 years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |